C12Y 302/02021
Dna-3-methyladenine glycosylase ii
Official title: DNA-3-methyladenine glycosylase II (3.2.2.21)
C12Y302/02021 (Dna-3-methyladenine glycosylase ii) appears on 2 US grants and 6 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2
- Published applications
- 6
- Assignees
- 5
- Inventors
- 12
- Latest grant
- 12 Mar 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Novel base editors and uses thereof8 Oct 2026US 2026/0308552 A1Huidagene Therapeutics (Singapore) Pte. Ltd.
- Programmable adenine base editor and uses thereof2 Oct 2025US 2025/0304940 A1Huidagene Therapeutics (Singapore) Pte. Ltd.
- Base Editing System for Achieving A-To-C and/or A-To-T Base Mutations and Use Thereof7 Aug 2025US 2025/0250586 A1East China Normal University
- Genetic signature of vulnerability to inhibitors of base excision repair (ber) in cancer20 Jul 2017US 2017/0204472 A1Dignity Health
- Genetic signature of vulnerability to inhibitors of base excision repair (ber) in cancer14 Apr 2016US 2016/0102360 A1Dignity Health
Most cited
By later US patents